| Product Unit Size | Cost | Quantity | Stock |
|---|
BMS-911543 is an oral selective inhibitor of JAK2 currently in clinical trials. BMS-911543 shows anticancer activity through inhibition of the JAK/STAT signaling cascade in in vitro and in vivo models of myeloproliferative neoplasms, which display constitutively active JAK2 signaling. This compound exhibits antiproliferative and anti-erythropoetic effects.
| Cas No. | 1271022-90-2 |
|---|---|
| Purity | ≥99% |
| Formula | C23H28N8O |
| Formula Wt. | 432.52 |
| IUPAC Name | N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide |
| Synonym | BMS911543 |
| Solubility | DMSO 36 mg/mL (83.23 mM) Ethanol 22 mg/mL (50.86 mM) Water Insoluble |
| Appearance | Off-White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. PMID: 22015772.
Tibes R, Bogenberger JM, Geyer HL, et al. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. PMID: 22991927.